Additional file 1 of Prevention of post-operative delirium using an overnight infusion of dexmedetomidine in patients undergoing cardiac surgery: a pragmatic, randomized, double-blind, placebo-controlled trial

Additional file 1. Table S1. Minimum and maximum dose of dexmedetomidine and its corresponding placebo administered every night (from 8 pm to 8 am) from Day 0 to Day 7. Table S2. All concomitant treatments administered from inclusion to Day 7 in both groups. Table S3. Main reason why CAM-ICU assessment and sleep quality evaluation were not performed or missing from Day 1 to Day 7. Table S4. Comparison of dexmedetomidine versus placebo on secondary outcomes: daily evaluation of sleep quality. Data are expressed as median and IQR. Table S5. Comparison of dexmedetomidine versus placebo on secondary outcomes: detailed sections of LSEQ during the 7 days of observation. Data are expressed as median and IQR. Table S6. Baseline creatinine level and daily renal component of the SOFA (Sequential Organ Failure Assessment) score. Table S7. Preplanned sub-group analysis for the primary outcome. Occurrence of PoD within the 7 days after surgery are expressed as number (%). Appendix 1. The cognitive failures questionnaire. Appendix 2. The PCL-5 standard form checklist. Appendix 3. The Leeds Sleep Evaluation Questionnaire (LSEQ). Each item is rated from -5 to +5. Negative score corresponded to negative effects on sleep quality.